Share this to:

Support & Insight for the Autumn of Life

New Alzheimer’s Drug Expediting FDA Trials

BREAKTHROUGH: The US Food and Drug Administration (FDA) has granted a “Breakthrough Therapy” designation for donanemab, a potential new treatment for people with early symptomatic Alzheimer’s. Find out more.


In June 2021 the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD).

The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available therapies that have received full FDA approval.

The FDA Breakthrough Therapy designation is based on clinical evidence for donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG.

The company’s Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic AD. These data were presented at the 15th International Conference on Alzheimer’s & Parkinson Diseases™ 2021 (AD/PD™ 2021) and published simultaneously in the New England Journal of Medicine.

Lilly intends to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later in 2021 based on data from TRAILBLAZER-ALZ.

The safety, tolerability and efficacy of donanemab are also being evaluated in the ongoing randomized, placebo-controlled, double-blind, multi-center Phase 3 study TRAILBLAZER-ALZ 2 (NCT04437511).

To learn more about the TRAILBLAZER-ALZ 2 study or to see if you prequalify, visit http://www.trailblazer2study.com.

About the TRAILBLAZER-ALZ Study

TRAILBLAZER-ALZ (NCT03367403) is a randomized, placebo-controlled, double-blind, multi-center Phase 2 study to assess the safety, tolerability and efficacy of donanemab in patients with early symptomatic Alzheimer’s disease.

The trial enrolled 272 patients who were selected based on cognitive assessments in conjunction with amyloid plaque imaging and tau staging by PET imaging.

The study’s primary endpoint was change from baseline until 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS), a composite tool combining the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog13) and the Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL) for function.

Key secondary endpoints included changes between baseline and 76 weeks in the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), ADCS-iADL, MMSE, and Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scores. Other secondary biomarker endpoints included changes from baseline to week 76 in brain amyloid deposition and brain tau deposition and volumetric MRI.

About Alzheimer’s Disease

Alzheimer’s disease is a fatal illness that causes progressive decline in memory and other aspects of cognition.

Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases. There are currently more than 50 million people living with dementia around the world, with numbers expected to increase to nearly 152 million by 20502.

Almost 10 million new cases of dementia are diagnosed each year worldwide, implying one new case every 3 seconds, and a significant increase in the caregiving burden placed on society and families. In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020.

The current annual societal and economic cost of dementia is estimated at $1 trillion, an amount that is expected to double by 2030 unless we find a way to slow the disease.

SOURCE:

REFERENCE:

  • Mark A. Mintun, Stephen P. Salloway et al.; Donanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2100708
Subscribe
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
B. Berger

B. Berger

Visit Our Pages On:

Welcome

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Related

12.12.23-brai.png
Clarifying Inflammation's Role in Alzheimer's
Researchers have long connected inflammation & Alzheimer's. Find out how interleukin-1 beta clarifies that connec...
130818-strok.jpeg
Men Treat Stroke Faster than Women
Women with strokes caused by blood clots arrive at the hospital an average 27 minutes later than men, a delay that ca...
150405-neuro.jpeg
Can My Doctor Diagnose & Treat Alzheimer's or Do I Need a Neurologist?
Dr. Geoffrey Kerchner is a memory disorders specialist at California's Memory Disorders Center. See him answer some i...

Books

Amazon Books
0
Would love your thoughts, please comment.x
()
x
News to Get at the Truth

Subscribe To Our Weekly Newsletter

Enjoy thought-provoking videos & articles
News to Get at the Truth

Subscribe To Our Weekly Newsletter